|Bid||1.0100 x 1200|
|Ask||1.0700 x 4000|
|Day's Range||0.9900 - 1.0700|
|52 Week Range||0.8400 - 4.4400|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022 - Aug 19, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Subscribe to Yahoo Finance Plus to view Fair Value for BIOC
SAN DIEGO, June 27, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today.
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’ ReSPECT-LM clinical trial AUSTIN, Texas and SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiot
SAN DIEGO, June 07, 2022--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.